Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ)...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of GUARD.ST is 1.8 and suggests 2% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Buy
Sell